Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ELEV Elevation Oncology
1.060-0.020-1.85%
Close
02/03 16:00 ET
1.0600.0000.00%
Post Mkt Price 02/03 16:36 ET
High
1.100
Open
1.050
Turnover
9.70K
Low
1.030
Pre Close
1.080
Volume
9.03K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Elevation Oncology, Inc. Forecasted to Post FY2023 Earnings of ($2.39) Per Share (NASDAQ:ELEV)
Elevation Oncology, Inc. (NASDAQ:ELEV – Get Rating) – Stock analysts at Wedbush increased their FY2023 earnings per share (EPS) estimates for shares of Elevation Oncology in a note issued to invest
Elevation Oncology Stock Price Target Cut to $4 From $6 at Wedbush
Elevation Oncology Stock Price Target Cut to $4 From $6 at Wedbush
Wedbush Lowers Elevation Oncology's Price Target to $4 From $6 After Announced Reprioritization of Development Efforts, Keeps Outperform Rating
07:30 AM EST, 01/23/2023 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersShuttle Pharmaceuticals (NASDAQ:SHPH) stock increased by 41.8% to $2.51 during Monday's pre-market session. The company's market cap stands at $33.9 million. Jasper Therapeutics (NASDAQ:JSPR) s
A Top Biden Administration Official Says The U.S. Government Will Announce A List Of 10 Prescription Drugs For Which It Plans To Negotiate Prices For Medicare Recipients On Sept. 1, And The Prices A Year Later
A Top Biden Administration Official Says The U.S. Government Will Announce A List Of 10 Prescription Drugs For Which It Plans To Negotiate Prices For Medicare Recipients On Sept. 1, And The Prices A Y
Elevation Oncology (NASDAQ:ELEV) Price Target Cut to $1.00 by Analysts at SVB Leerink
Elevation Oncology (NASDAQ:ELEV – Get Rating) had its price target cut by analysts at SVB Leerink from $2.00 to $1.00 in a report released on Monday, Benzinga reports. The firm presently has a "mark
SVB Securities Cuts Price Target on Elevation Oncology to $1 From $2, Maintains Market Perform Rating
07:43 AM EST, 01/09/2023 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Analysts' Opinions Are Mixed on These Healthcare Stocks: Viridian Therapeutics (VRDN), Amryt Pharma (AMYT) and Elevation Oncology (ELEV)
Elevation Oncology Price Target Cut to $1.00/Share From $2.00 by SVB Leerink
Elevation Oncology Is Maintained at Market Perform by SVB Leerink
Company Overview
More
Elevation Oncology, Inc. operates as a precision oncology company. It focuses on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The firm’s program is focused on patients with advanced solid tumors harboring an NRG1 fusion. The company was founded by Shawn M. Leland in 2019 and is headquartered in New York, NY.
CEO： Mr. Joseph J. Ferra
Market： NASDAQ
Listing Date： 06/25/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet